Functional evidence implicating S100P in prostate cancer progression

Gargi D. Basu, David O. Azorsa, Jeffrey A. Kiefer, Angela M. Rojas, Sukru Tuzmen, Michael T. Barrett, Jeffrey M. Trent, Olli Kallioniemi, Spyro Mousses (Corresponding Author)

Research output: Contribution to journalArticleScientificpeer-review

48 Citations (Scopus)

Abstract

S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction, protein phosphorylation and transcriptional control. We have previously shown how elevated S100P levels in prostate cancer strongly correlate with progression to metastatic disease. In our study, we evaluated the functional significance of S100P expression on prostate tumor growth in vitro and in vivo. S100P levels were modulated by overexpressing S100P in PC3 prostate cancer cells and by silencing S100P levels in 22Rv1 prostate cancer cells. Overexpression of S100P in PC3 cells promoted cell growth, increased the percentage of S‐phase cells, decreased basal apoptosis rate and promoted anchorage independent growth in soft agar. Furthermore, prostate cancer cells overexpressing S100P were protected against camptothecin‐induced apoptosis. Conversely, silencing of S100P in 22Rv1 cells using siRNA resulted in a prominent cytostatic effect. The influence of S100P on tumor growth and metastases were assessed in vivo. S100P‐overexpressing PC3 cells had a dramatically increased tumor formation compared to controls. Microarray analysis showed the involvement of growth pathways including increased androgen receptor expression in S100P‐overexpressing cells. These results provide the first functional proof that S100P overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth. Moreover, the results confirm the oncogenic nature of S100P in prostate cancer and suggest that the protein may directly confer resistance to chemotherapy. Hence, S100P could be considered a potential drug target or a chemosensitization target, and could also serve as a biomarker for aggressive, hormone‐refractory and metastatic prostate cancer.
Original languageEnglish
Pages (from-to)330-339
JournalInternational Journal of Cancer
Volume123
Issue number2
DOIs
Publication statusPublished - 2008
MoE publication typeA1 Journal article-refereed

Fingerprint

Prostatic Neoplasms
Growth
Androgen Receptors
Apoptosis
Neoplasms
Cytoskeletal Proteins
Cytostatic Agents
Microarray Analysis
Small Interfering RNA
Agar
Prostate
Signal Transduction
Proteins
Up-Regulation
Biomarkers
Phosphorylation
Neoplasm Metastasis
Calcium
Drug Therapy
Pharmaceutical Preparations

Keywords

  • prostate cancer
  • S100P
  • xenograft

Cite this

Basu, G. D., Azorsa, D. O., Kiefer, J. A., Rojas, A. M., Tuzmen, S., Barrett, M. T., ... Mousses, S. (2008). Functional evidence implicating S100P in prostate cancer progression. International Journal of Cancer, 123(2), 330-339. https://doi.org/10.1002/ijc.23447
Basu, Gargi D. ; Azorsa, David O. ; Kiefer, Jeffrey A. ; Rojas, Angela M. ; Tuzmen, Sukru ; Barrett, Michael T. ; Trent, Jeffrey M. ; Kallioniemi, Olli ; Mousses, Spyro. / Functional evidence implicating S100P in prostate cancer progression. In: International Journal of Cancer. 2008 ; Vol. 123, No. 2. pp. 330-339.
@article{4705b5404985487fabc07c1c2896055f,
title = "Functional evidence implicating S100P in prostate cancer progression",
abstract = "S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction, protein phosphorylation and transcriptional control. We have previously shown how elevated S100P levels in prostate cancer strongly correlate with progression to metastatic disease. In our study, we evaluated the functional significance of S100P expression on prostate tumor growth in vitro and in vivo. S100P levels were modulated by overexpressing S100P in PC3 prostate cancer cells and by silencing S100P levels in 22Rv1 prostate cancer cells. Overexpression of S100P in PC3 cells promoted cell growth, increased the percentage of S‐phase cells, decreased basal apoptosis rate and promoted anchorage independent growth in soft agar. Furthermore, prostate cancer cells overexpressing S100P were protected against camptothecin‐induced apoptosis. Conversely, silencing of S100P in 22Rv1 cells using siRNA resulted in a prominent cytostatic effect. The influence of S100P on tumor growth and metastases were assessed in vivo. S100P‐overexpressing PC3 cells had a dramatically increased tumor formation compared to controls. Microarray analysis showed the involvement of growth pathways including increased androgen receptor expression in S100P‐overexpressing cells. These results provide the first functional proof that S100P overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth. Moreover, the results confirm the oncogenic nature of S100P in prostate cancer and suggest that the protein may directly confer resistance to chemotherapy. Hence, S100P could be considered a potential drug target or a chemosensitization target, and could also serve as a biomarker for aggressive, hormone‐refractory and metastatic prostate cancer.",
keywords = "prostate cancer, S100P, xenograft",
author = "Basu, {Gargi D.} and Azorsa, {David O.} and Kiefer, {Jeffrey A.} and Rojas, {Angela M.} and Sukru Tuzmen and Barrett, {Michael T.} and Trent, {Jeffrey M.} and Olli Kallioniemi and Spyro Mousses",
year = "2008",
doi = "10.1002/ijc.23447",
language = "English",
volume = "123",
pages = "330--339",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley",
number = "2",

}

Basu, GD, Azorsa, DO, Kiefer, JA, Rojas, AM, Tuzmen, S, Barrett, MT, Trent, JM, Kallioniemi, O & Mousses, S 2008, 'Functional evidence implicating S100P in prostate cancer progression', International Journal of Cancer, vol. 123, no. 2, pp. 330-339. https://doi.org/10.1002/ijc.23447

Functional evidence implicating S100P in prostate cancer progression. / Basu, Gargi D.; Azorsa, David O.; Kiefer, Jeffrey A.; Rojas, Angela M.; Tuzmen, Sukru; Barrett, Michael T.; Trent, Jeffrey M.; Kallioniemi, Olli; Mousses, Spyro (Corresponding Author).

In: International Journal of Cancer, Vol. 123, No. 2, 2008, p. 330-339.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Functional evidence implicating S100P in prostate cancer progression

AU - Basu, Gargi D.

AU - Azorsa, David O.

AU - Kiefer, Jeffrey A.

AU - Rojas, Angela M.

AU - Tuzmen, Sukru

AU - Barrett, Michael T.

AU - Trent, Jeffrey M.

AU - Kallioniemi, Olli

AU - Mousses, Spyro

PY - 2008

Y1 - 2008

N2 - S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction, protein phosphorylation and transcriptional control. We have previously shown how elevated S100P levels in prostate cancer strongly correlate with progression to metastatic disease. In our study, we evaluated the functional significance of S100P expression on prostate tumor growth in vitro and in vivo. S100P levels were modulated by overexpressing S100P in PC3 prostate cancer cells and by silencing S100P levels in 22Rv1 prostate cancer cells. Overexpression of S100P in PC3 cells promoted cell growth, increased the percentage of S‐phase cells, decreased basal apoptosis rate and promoted anchorage independent growth in soft agar. Furthermore, prostate cancer cells overexpressing S100P were protected against camptothecin‐induced apoptosis. Conversely, silencing of S100P in 22Rv1 cells using siRNA resulted in a prominent cytostatic effect. The influence of S100P on tumor growth and metastases were assessed in vivo. S100P‐overexpressing PC3 cells had a dramatically increased tumor formation compared to controls. Microarray analysis showed the involvement of growth pathways including increased androgen receptor expression in S100P‐overexpressing cells. These results provide the first functional proof that S100P overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth. Moreover, the results confirm the oncogenic nature of S100P in prostate cancer and suggest that the protein may directly confer resistance to chemotherapy. Hence, S100P could be considered a potential drug target or a chemosensitization target, and could also serve as a biomarker for aggressive, hormone‐refractory and metastatic prostate cancer.

AB - S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction, protein phosphorylation and transcriptional control. We have previously shown how elevated S100P levels in prostate cancer strongly correlate with progression to metastatic disease. In our study, we evaluated the functional significance of S100P expression on prostate tumor growth in vitro and in vivo. S100P levels were modulated by overexpressing S100P in PC3 prostate cancer cells and by silencing S100P levels in 22Rv1 prostate cancer cells. Overexpression of S100P in PC3 cells promoted cell growth, increased the percentage of S‐phase cells, decreased basal apoptosis rate and promoted anchorage independent growth in soft agar. Furthermore, prostate cancer cells overexpressing S100P were protected against camptothecin‐induced apoptosis. Conversely, silencing of S100P in 22Rv1 cells using siRNA resulted in a prominent cytostatic effect. The influence of S100P on tumor growth and metastases were assessed in vivo. S100P‐overexpressing PC3 cells had a dramatically increased tumor formation compared to controls. Microarray analysis showed the involvement of growth pathways including increased androgen receptor expression in S100P‐overexpressing cells. These results provide the first functional proof that S100P overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth. Moreover, the results confirm the oncogenic nature of S100P in prostate cancer and suggest that the protein may directly confer resistance to chemotherapy. Hence, S100P could be considered a potential drug target or a chemosensitization target, and could also serve as a biomarker for aggressive, hormone‐refractory and metastatic prostate cancer.

KW - prostate cancer

KW - S100P

KW - xenograft

U2 - 10.1002/ijc.23447

DO - 10.1002/ijc.23447

M3 - Article

VL - 123

SP - 330

EP - 339

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -

Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT et al. Functional evidence implicating S100P in prostate cancer progression. International Journal of Cancer. 2008;123(2):330-339. https://doi.org/10.1002/ijc.23447